How effective is Sutent for GIST?
The objective clinical benefit was achieved in approximately 60% of GIST patients who received sunitinib after failure of prior imatinib treatment [11–14]. Median progression -free survival time on sunitinib is 6-8 months. The adverse events reported during this therapy are frequent.
Is sunitinib better than imatinib?
In a subgroup analysis of patients without exon 9 mutation, sunitinib had significantly better PFS than imatinib dose escalation (median = 14.3 months versus 6.2 months; p < 0.037) but the OS was comparable between the two treatment groups [16].
Can metastatic GIST be cured?
Although TKI therapies have revolutionized the treatment of recurrent or metastatic GISTs, they cannot cure GISTs.
Can you survive gist?
GIST may be curable if there is one early stage tumor that can be surgically removed without damaging vital organs. This can sometimes be done with minimally invasive laparoscopic surgery. Some people make a full recovery without needing further treatment.
Can imatinib cure gist?
This drug targets both the KIT and PDGFRA proteins, blocking their ability to help tumor cells grow and divide. In most GISTs, the cells have too much of one of these proteins. Most GISTs shrink when treated with imatinib. Some other tumors at least stop growing for a time.
Who makes sunitinib?
Sunitinib is marketed by Pfizer as Sutent, and is subject to patents and market exclusivity as a new chemical entity until February 15, 2021.
How long can I live with GIST?
5-year relative survival rates for GIST
| SEER Stage | 5-Year Relative Survival Rate |
|---|---|
| Localized | 93% |
| Regional | 81% |
| Distant | 53% |
| All SEER stages combined | 83% |
How long can you live with Stage 4 GIST?
Overall survival rates for patients with GISTs were 88% at 1 year, 77% at 2 years, 67% at 3 years, and 51% at 5 years. Based on multivariable Cox proportional hazard models, investigators found that primary treatment for GISTs independently affected overall survival.
What is life expectancy with GIST tumor?
Survival rates can give you an idea of what percentage of people with the same type and stage of cancer are still alive a certain amount of time (usually 5 years) after they were diagnosed….5-year relative survival rates for GIST.
| SEER Stage | 5-Year Relative Survival Rate |
|---|---|
| Distant | 53% |
| All SEER stages combined | 83% |
Does sunitinib therapy improve progression-free survival in GIST?
Prior et al (2008) correlated PET results for GIST patients after 4 weeks of sunitinib therapy with their duration of Progression-Free Survival (PFS) on the drug.
How many patients were in the sunitinib study?
The 32 patients Dr. Maki described in the continuation study comprise over half of the 55 patients in the Phase II study referred to as “Study B” in the sunitinib prescribing information and in the slides shown at www.sutent.com . The primary endoint of the Phase II study was objective response rate, as defined by RECIST.
How effective is sunitinib for the treatment of metastatic lung cancer?
Sunitinib was effective against tumors with secondary mutations in exon 13 or 14, but not against those with secondary mutations in exon 17 or 18. Importantly, patients may harbor different secondary mutations in different metastatic lesions. Therefore, sunitinib may control some of a patient’s tumors, while others are unresponsive.
Is sunitinib better for exon-9-mutation patients?
The greater clinical benefit of sunitinib for exon-9-mutation and wildtype patients occurs because these patients are unlikely to develop secondary mutations; only 19% of exon-9 patients developed secondary mutations, and none of the wildtype patients.